Veverimer is a non-absorbed polymer designed to selectively remove acid from the human body.
Veverimer (also known as TRC101)
Our investigational drug candidate, veverimer, is a novel, non-absorbed polymer that is designed to bind hydrochloric acid in the gastrointestinal tract and remove it from the body through excretion in the feces. Veverimer is administered orally as a suspension in water. Veverimer is specifically designed to combine high capacity and high selectivity for binding and removing hydrochloric acid. Importantly, veverimer does not deliver sodium or other counterions, potentially allowing for chronic treatment of metabolic acidosis in patients with chronic kidney disease (CKD) and common comorbidities such as hypertension, cardiovascular disease, heart failure or edema, if approved.
Veverimer: Designed to Bind and Remove Hydrochloric Acid (HCl) with High Capacity and Selectivity
Tricida Recently Completed the VALOR-CKD Trial to Evaluate Veverimer as a Potential Treatment to Slow CKD Progression through the Treatment of Metabolic Acidosis
The VALOR-CKD Trial
The VALOR-CKD trial was an international, randomized, multicenter, double-blind, placebo-controlled trial of patients with CKD and metabolic acidosis. A single-blind active-treatment period of 4-8 weeks (Part A) preceded the double-blind, randomized treatment period (Part B). Patients in Part A who experienced a greater than or equal to 4 mEq/L increase in serum bicarbonate and those whose serum bicarbonate increased into the normal range of greater than or equal to 22 mEq/L were randomized in a 1:1 ratio to continued veverimer treatment or to placebo treatment for the double-blind, Part B, portion of the trial.
VALOR-CKD Renal Outcomes Trial
The primary endpoint in the VALOR-CKD trial was defined as time to first occurrence of any event in the composite of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. In October 2022, Tricida reported top-line results from the VALOR-CKD trial, indicating that the trial did not meet its primary endpoint.